1Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2 [J]. J Biol Chem, 2008, 283 (4) : 2363- 2372. 被引量：1
2Grefhorst A, Mcnutt MC, Lagace TA, et al. Plasma PCSK9 preferentially reduces liver LDL receptors in mice[J]. J Lipid Res,2008,49(6) :1303-1311. 被引量：1
3Benjannet S, Hamelin J, Chretien M, et al. Loss-and gain-of- function PCSK9 variants cleavage specificity, dominant negative effects,and low density lipoprotein receptor(LDLR) degradation[J]. J Bio Chem, 2012,287(40) : 33745-33755. 被引量：1
5Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiationEJ3. Proc Natl Acad Sei USA,2003,100(3) :928-933. 被引量：1
6Abifadel M, Guerin M, Benjannet S, et al. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal hypereholesterolemia[J]. Atherosclerosis, 2012,223 400. dominant (2) : 394-. 被引量：1
7Kosenko T, Golder lipoprotein binds to M, Leblond G, et al. Low density proprotein convertase subtilisin/kexin type-9(PCSK9)in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation[J]. J Biol Chem, 2013,288(12) :8279-8288. 被引量：1
8Leren TP. Sorting an LDL receptor with bound PCSK9 to intracellular degradation[J]. Atherosclerosis, 2014,237(1 ) : 76- 81. 被引量：1
9Cariou B, Le May C, Coster P. Clinical aspects of PCSK9[J]. Atherosclerosis, 2011,216 (2) :258-265. 被引量：1
10Zhang Y, Liu J, Li S, et al. Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration., single or in combination study in rats[J]. Lipids Health Dis, 2014,13 35-46. 被引量：1
二级参考文献160
1Abifadel M, Rabes J P, Boileau C, et al. After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist: PCSK9 [ J]. Ann Endocrinol (Paris) ,2007, 68(2-3) : 138-146. 被引量：1
2Martin B, Solanas-Barca M, Garcia-Otin A L, et al. An NPC1L1 gene promoter variant is associated with autosomal dominant hypercholesterolemia[ J]. Nutr Metab Cardiovasc Dis, 2010,20(4) :236-242. 被引量：1
3Varret M, Abifadel M, Rabes J P, et al. Genetic heterogeneity of autosomal dominant hypercholesterolemia [ J ]. Clin Genet, 2008,73(1 ) :1-13. 被引量：1
4Lopez D. PCSK9 : an enigmatic protease [ J]. Biochim Biophys Acta, 2008,1781 ( 4 ) : 184-191. 被引量：1
5Lambert G, Charlton F, Rye K A, et al. Molecular basis of PCSK9 function [J]. Atherosclerosis,2009, 203 ( 1 ) : 1-7. 被引量：1
6Homer V M, Marais A D, Charhon F, et al. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa[J]. Atherosclerosis,2008,196(2) :659-666. 被引量：1
7Hallman D M, Srinivasan S R, Chen W, et al. Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood(from The Bogalusa Heart Study) [ J]. Am J Cardiol,2007, 100( 1 ) : 69-72. 被引量：1
8Cohen J, Pertsemlidis A, Kotowski I K, et al. Low LDL cholesterol in individuals of African descent resulting from frequerit nonsense mutations in PCSK9 [ J]. Nat Genet,2005,37 (2) :161-165. 被引量：1
9Mayne J, Dewpura T, Raymond A, et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans [ J ]. Lipids Health Dis,2008,7:22. 被引量：1
10Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) : hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration [ J ]. Hepatology, 2008,48 ( 2 ) : 646 -654. 被引量：1
